The purpose of this study is to evaluate the efficacy of clarithromycin in eradication of ureaplasma urealyticum and prevention of chronic lung disease in premature infants with birthweight \< 1250 g and have ureaplasma urealyticum colonization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
273
Zekai Tahir Burak Maternity Teaching Hospital Neonatology department
Ankara, Turkey (Türkiye)
To evaluate the efficacy of clarithromycin in eradication of Ureaplasma urealyticum from premature nasopharynges
Efficacy of clarithromycin in eradication of Ureaplasma and incidence of CLD were the major outcomes of the study. Nasopharyngeal swabs for Ureaplasma were taken in postnatal first 3 days and on the 12th day only in culture positive infants, transported to the laboratory and cultured for Uu immediately.
Time frame: 12 days after treatment by clarithromycin
To evaluate the efficacy of clarithromycin in prevention of Chronic lung disease in premature infants with birthweight <1250 g and have Ureaplasma urealyticum colonization.
Efficacy of clarithromycin in eradication of Ureaplasma urealyticum and incidence of chronic lung disease were the major outcomes of the study. Chronic lung disease of newborn was defined as a persistent oxygen requirement at 36 weeks post menstrual age or death.
Time frame: From first day of inclusion of study to at postpartum 36th week of day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.